Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 222

1.

Analysis of Wnt gene expression in prostate cancer: mutual inhibition by WNT11 and the androgen receptor.

Zhu H, Mazor M, Kawano Y, Walker MM, Leung HY, Armstrong K, Waxman J, Kypta RM.

Cancer Res. 2004 Nov 1;64(21):7918-26. Erratum in: Cancer Res. 2005 Sep 1;65(17):8057.

2.

Effects of WNT/beta-catenin pathway activation on signaling through T-cell factor and androgen receptor in prostate cancer cell lines.

Cronauer MV, Schulz WA, Ackermann R, Burchardt M.

Int J Oncol. 2005 Apr;26(4):1033-40.

PMID:
15753999
3.
4.

Ligand-dependent inhibition of beta-catenin/TCF signaling by androgen receptor.

Chesire DR, Isaacs WB.

Oncogene. 2002 Dec 5;21(55):8453-69.

5.

WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics.

Bisson I, Prowse DM.

Cell Res. 2009 Jun;19(6):683-97. doi: 10.1038/cr.2009.43.

PMID:
19365403
6.

Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.

Zaia A, Fraizer GC, Piantanelli L, Saunders GF.

Anticancer Res. 2001 Jan-Feb;21(1A):1-10.

PMID:
11299720
7.

Relaxin drives Wnt signaling through upregulation of PCDHY in prostate cancer.

Thompson VC, Hurtado-Coll A, Turbin D, Fazli L, Lehman ML, Gleave ME, Nelson CC.

Prostate. 2010 Jul 1;70(10):1134-45. doi: 10.1002/pros.21148.

PMID:
20503398
8.

Multiple mechanisms for Wnt11-mediated repression of the canonical Wnt signaling pathway.

Maye P, Zheng J, Li L, Wu D.

J Biol Chem. 2004 Jun 4;279(23):24659-65. Epub 2004 Apr 2.

9.

Beta-catenin signaling in prostate cancer: an early perspective.

Chesire DR, Isaacs WB.

Endocr Relat Cancer. 2003 Dec;10(4):537-60. Review.

10.

A human- and male-specific protocadherin that acts through the wnt signaling pathway to induce neuroendocrine transdifferentiation of prostate cancer cells.

Yang X, Chen MW, Terry S, Vacherot F, Chopin DK, Bemis DL, Kitajewski J, Benson MC, Guo Y, Buttyan R.

Cancer Res. 2005 Jun 15;65(12):5263-71.

11.

A direct beta-catenin-independent interaction between androgen receptor and T cell factor 4.

Amir AL, Barua M, McKnight NC, Cheng S, Yuan X, Balk SP.

J Biol Chem. 2003 Aug 15;278(33):30828-34. Epub 2003 Jun 10.

12.

Identification of aryl hydrocarbon receptor as a putative Wnt/beta-catenin pathway target gene in prostate cancer cells.

Chesire DR, Dunn TA, Ewing CM, Luo J, Isaacs WB.

Cancer Res. 2004 Apr 1;64(7):2523-33.

13.

Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.

Murthy S, Agoulnik IU, Weigel NL.

Prostate. 2005 Sep 1;64(4):362-72.

PMID:
15754350
14.

Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth.

Mazor M, Kawano Y, Zhu H, Waxman J, Kypta RM.

Oncogene. 2004 Oct 14;23(47):7882-92.

PMID:
15361837
15.

Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer.

Horvath LG, Lelliott JE, Kench JG, Lee CS, Williams ED, Saunders DN, Grygiel JJ, Sutherland RL, Henshall SM.

Prostate. 2007 Jul 1;67(10):1081-90.

PMID:
17476687
16.

Beta-catenin affects androgen receptor transcriptional activity and ligand specificity.

Truica CI, Byers S, Gelmann EP.

Cancer Res. 2000 Sep 1;60(17):4709-13.

17.

The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens.

Schweizer L, Rizzo CA, Spires TE, Platero JS, Wu Q, Lin TA, Gottardis MM, Attar RM.

BMC Cell Biol. 2008 Jan 24;9:4. doi: 10.1186/1471-2121-9-4.

18.

Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10.

Ishikura N, Kawata H, Nishimoto A, Nakamura R, Ishii N, Aoki Y.

Prostate. 2010 Apr 1;70(5):457-66. doi: 10.1002/pros.21079.

PMID:
19902465
19.

SOX9 is expressed in normal prostate basal cells and regulates androgen receptor expression in prostate cancer cells.

Wang H, McKnight NC, Zhang T, Lu ML, Balk SP, Yuan X.

Cancer Res. 2007 Jan 15;67(2):528-36.

20.

Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells.

de la Taille A, Rubin MA, Chen MW, Vacherot F, de Medina SG, Burchardt M, Buttyan R, Chopin D.

Clin Cancer Res. 2003 May;9(5):1801-7.

Supplemental Content

Support Center